Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ArriVent in Hunt for $145 Million to Finance US In-licensing Operations

publication date: Jan 4, 2023

ArriVent Biopharma of Philadelphia is raising another $145 million to bring drugs from China and other emerging biotech hubs to the US market. So far, the company has commitments for $110 million of the total. 18 months ago, ArriVent broke cover with news of a $150 million initial funding from China investors and a single development project: a potentially best-in-class EGFR TKI inhibitor, furmonertinib, in-licensed from Shanghai's Allist Pharma. Last summer, ArriVent began a US Phase Ib trial of furmonertinib in advanced or metastatic non-small cell lung cancer patients with EGFR or HER2 mutations. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital